相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Oxidative Stress Contributes to Soluble Fms-Like Tyrosine Kinase-1 Induced Vascular Dysfunction in Pregnant Rats
Jason P. Bridges et al.
AMERICAN JOURNAL OF HYPERTENSION (2009)
Placental growth factor is a potent vasodilator of rat and human resistance arteries
George Osol et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia
Valeria C. Sandrim et al.
HYPERTENSION (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia
Zhihe Li et al.
HYPERTENSION (2007)
Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia
Akihide Ohkuchi et al.
HYPERTENSION RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity
Patricia Parsons-Wingerter et al.
MICROVASCULAR RESEARCH (2006)
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
Richard J. Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mechanisms of endothelial response to oxidative aggression:: Protective role of autologous VEGF and induction of VEGFR2 by H2O2
Francisco R. Gonzalez-Pacheco et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Increased collagen content in insulin-resistant skeletal muscle
R Berria et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Soluble endoglin contributes to the pathogenesis of preeclampsia
Shivalingappa Venkatesha et al.
NATURE MEDICINE (2006)
Circulating angiogenic factors and the risk of preeclampsia
RJ Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prospective analysis of placenta growth factor (PIGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia
T Krauss et al.
HYPERTENSION IN PREGNANCY (2004)
Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IκB/NF-κB
MR Abid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria
H Sugimoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
B Li et al.
HYPERTENSION (2002)
Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians
S Yamaguchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
CJ Kuo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene
H Chen et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2000)
Causes of maternal mortality in Japan
K Nagaya et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)